middle.news
Acrux Secures $1.6 Million Placement to Back Female Testosterone Trials
11:32am on Monday 11th of May, 2026 AEST
•
Healthcare
Read Story
Acrux Secures $1.6 Million Placement to Back Female Testosterone Trials
11:32am on Monday 11th of May, 2026 AEST
Key Points
Raised $1.6 million via share placement at 0.95 cents
Placement scaled back from $2.6 million in bids
Attaching options offered at 1.8 cents, 3-year term
Funds to advance female testosterone Phase III trials
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Acrux (ASX:ACR)
OPEN ARTICLE